The global chronic pain market size accounted for USD 50,618 million in 2024 and is expected to exceed around USD 75,651 million by 2034, growing at a CAGR of 4.1% from 2024 to 2034.
The chronic pain market refers to the commercial sector industry, which includes the manufacturing and distribution of medication, treatments, and medical devices that are used to treat or manage chronic disease conditions that usually last longer than the typical pain injury or illness. Chronic conditions such as arthritis, fibromyalgia, back pain, cancer pain, and neuropathic pain can cause long-term pain and discomfort, which requires management. Lack of proper pain management can lead to a number of mental health issues and even result in drug addiction. The products that are used in the market are pain medications (opioids, NSAIDs), neuromodulators, and therapies that are widely deployed, especially as the global population ages and suffers more from chronic conditions. The market growth is driven by the prevalence of chronic disease, increased awareness about pain management, and the aging population.
The key restraints faced by the market include growing hesitance among healthcare providers to prescribe potentially addictive pain medication. Despite this, the chronic pain market is expected to grow in the future due to pharmaceutical and biomedical advancements in pain management, the increasing demand for non-addictive medications, increased healthcare expenditure, rising access to treatment, changes in consumer lifestyles in terms of food consumption among the younger population, pollution, and other environmental issues. The increasing incidence of painkiller abuse is prompting physicians to opt for non-opioid therapies.
Published by Ajit Bansod
